---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-016892"
form_type: "8-K"
ticker: "CPIX"
cik: "0001087294"
company_name: "CUMBERLAND PHARMACEUTICALS INC"
filed_at: "2023-05-09T23:59:59+00:00"
generated_at: "2026-06-15T08:02:36.175575+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Cumberland Pharma Q1 net revenue $9.2M, adj. EPS $0.11; expects Caldolor Medicare boost under NOPAIN Act

## Summary
- Q1 2023 net revenues of $9.2M; net income of $0.2M ($0.01 EPS); adjusted earnings of $1.7M ($0.11 EPS).
- Product revenue: Kristalose $4.3M, Sancuso $1.9M, Vibativ $1.8M, Caldolor $0.9M.
- Caldolor expected to qualify for separate Medicare reimbursement under the NOPAIN Act, enacted April 2023.
- FDA granted barrier-to-innovation waiver, refunding nearly $2M in RediTrex prescription drug program fees.
- Balance sheet: $89M assets, $16M cash, $53M liabilities (including $16M drawn on revolver), $36M equity.

## SEC filing metadata
- accession: 0001628280-23-016892
- form_type: 8-K
- ticker: CPIX
- cik: 0001087294
- company_name: CUMBERLAND PHARMACEUTICALS INC
- filed_at: 2023-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1087294/000162828023016892/0001628280-23-016892-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1087294/000162828023016892/cpix-20230509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-016892
- JSON: https://secwatch.observer/filing/0001628280-23-016892.json
- Plain text: https://secwatch.observer/filing/0001628280-23-016892.txt

## Key facts
- Earnings Releases
  CUMBERLAND PHARMACEUTICALS INC reported the first quarter of 2023 results: revenue $9.2 million, net income $0.2 million or $0.01 a share, EPS $0.01 a share.
  - Period: the first quarter of 2023
  - Revenue: $9.2 million
  - Net income: $0.2 million or $0.01 a share
  - EPS: $0.01 a share
  - Result: reported results
  source text: Cumberland Pharmaceuticals Reports First Quarter 2023 Financial Results & Company Update NASHVILLE, TENNESSEE (Tuesday, May 9, 2023) - Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) , a specialty pharmaceutical company, today announced that the Company’s product portfolio of FDA-approved brands delivered combined revenues of $9.2 million during the first quarter of 2023. Net income for the period was $0.2 million, or $0.01 a share, resulting in adjusted earnings of $1.7 million, or $0.11 a share.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1087294/000162828023016892/0001628280-23-016892-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.